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Abstract 25 
Osteoarthritis (OA) is the most common joint disorder in the world but there are no 26 
approved therapeutics to prevent disease progression.  Historically, OA has been 27 
considered a wear and tear joint disease and efforts to identify and develop disease 28 
modifying therapeutics have predominantly focussed on direct inhibition of cartilage 29 
degeneration. However, there is now increasing evidence that inflammation is a key 30 
mediator of OA joint pathology and also that the link between obesity and OA is not 31 
solely due to excessive load-bearing, suggesting therefore that targeting 32 
inflammation in OA could be a rewarding therapeutic strategy.  In this review we 33 
therefore re-evaluate historical clinical trial data on anti-inflammatory therapeutics in 34 
OA patients, highlight some of the more promising emerging therapeutic targets and 35 
discuss the implications for future clinical trial design.  36 
  37 
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Osteoarthritis and inflammation 38 
Inflammation in OA has been overlooked for many years.. However, histological 39 
analysis, ultrasound and MRI imaging have shown evidence of synovitis in OA joints 40 
[1] with increased cellular infiltration of activated B cells and T lymphocytes. 41 
Histological studies indicate that synovitis is present in 50% of patients with early  42 
OA, and in nearly all patients with late-stage OA [2]. Furthermore, synovial 43 
hypertrophy as detected by ultrasound has been shown to correlate to knee OA 44 
disease severity [3]. 45 
 46 
Several studies have reported elevated levels of a number of pro-inflammatory 47 
mediators (including TNF-α, IL-1β, IL-6, IL-15, IL-17, IL-18 and NO)  in the serum or 48 
synovial fluid of OA patients [4, 5], compared to healthy patients (Figure 1). 49 
Furthermore, stimulation of cartilage tissue with pro-inflammatory cytokines mimics 50 
many of the structural changes associated with OA [6-8].   51 
 52 
In light of this , it is perhaps surprising that clinical studies in OA patients with anti-53 
inflammatory therapeutics have thus far disappointed.  However, OA pathology is 54 
highly heterogeneous, with the degree of synovitis varying amongst patients.  55 
Indeed, synovitis is not present in half of patients with early OA [2].  Therefore, 56 
patient selection is an important consideration for such clinical studies, and unless 57 
taken into account could impact on whether the clinical end point is met.  For this 58 
reason, we re-evaluate the clinical trial data of anti-inflammatory therapeutics in OA 59 
(Table 1), to highlight in particular the specific OA patient cohort studied, whether 60 
patients were selected for synovitis and the clinical end-points measured.  This is not 61 
a systematic review.  Instead, we have focussed on completed randomised control 62 
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trials (RCTs) conducted during the last 10 years in patients with hand, knee and hip 63 
OA, which have reported clinical end-points.    Secondly, we explore the 64 
opportunities for the development of new targeted therapeutics (Table 2) and discuss 65 
the requirement to stratify patients for such approaches. 66 
  67 
Anti-inflammatory therapeutics in OA patients 68 
Anti TNF-α therapies 69 
In OA joint tissues, synovial fluid, and serum, TNF-α has been reported to be 70 
elevated compared to healthy patients [9-11]. In rodent models of traumatic joint 71 
injury, TNF-α expression is induced [12] and correlates to joint space narrowing 72 
(JSN) [13]. Furthermore, overproduction of TNF-α induces NO [14], and upregulates 73 
the expression of MMPs [15], whilst TNF-α receptor antagonists block NO production 74 
in human cartilage tissue [16]. TNF-α has also been demonstrated to inhibit 75 
proteoglycan [17] and Type II collagen  synthesis.  However, despite these data and 76 
the proven successes in treating rheumatoid arthritis (RA) patients with anti-TNF-α 77 
therapeutics, clinical trials in OA patients have yielded conflicting and generally 78 
disappointing results. 79 
 80 
Adalimumab (Humira; Abbott Laboratories, IL) is a human monoclonal antibody 81 
(mAb) bioengineered to bind to TNF-α and prevent receptor binding [18]. It has been 82 
shown to be efficacious in reducing the pathological symptoms of RA in several 83 
clinical trials(DE001/003, DE004, DE007, DE009, and DE010) [18]. However, its effect on OA 84 
disease modification has not been clinically proven. 85 
 86 
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In a PhII, 12 month RCT(NCT00296894), 60 patients with active erosive hand OA 87 
received Adalimumab (40mg) or placebo subcutaneously every two weeks. 88 
Progression from palpable soft tissue swelling to joint damage decreased 10-fold in 89 
the Adalimumab group compared to placebo [19], with a reduction in the proportion 90 
of patients experiencing a new erosive interphalangeal joint at 12 month follow-up  91 
(26.7%vs 40% placebo control),  However these findings did not reach statistical 92 
significance and  Adalimumab was deemed ineffective at reducing disease activity 93 
[19].  94 
 95 
In a PhI/II study of 17 patients with knee OA(NCT00686439), Adalimumab (40mg, every 2 96 
weeks) resulted in significant improvements in joint pain at 12 weeks with WOMAC 97 
20% and WOMAC 50% responses in 70% and 40% of patients respectively [20]. 98 
However, this study did not incorporate measures of disease modification including 99 
JSN, so it is unknown whether prolonged treatment with Adalimumab in this patient 100 
cohort would ultimately be disease-modifying. Furthermore, Adalimumab failed to 101 
reach its primary end-point of improving pain in a PhII study(NCT00597623) in patients 102 
with hand OA refractory to standard-of-care analgesics [21].  103 
 104 
It is clear that anti-TNF-α therapeutics are far less efficacious in improving OA pain 105 
and joint mobility compared to the outcomes achieved in RA patients. Indeed, RA is 106 
a more inflammatory condition with greater evidence of TNF-α and immune cell 107 
involvement.  However, some positive results have been reported with Adalimumab 108 
in patients with knee OA and in patients with erosive hand OA. It should be stressed 109 
that these clinical studies did not measure disease progression, and likely involved 110 
highly heterogeneous OA patient cohorts. Despite several pilot studies(NCT01144143) 111 
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[22],  and small RCTs (NCT00819572) [23] , larger placebo RCTs to determine the 112 
efficacy of other anti-TNF-α therapies such as infliximab and DLX105 (TNF-α  mAb) 113 
have not yet been undertaken to fully evaluate the potential of TNF-α therapeutics in 114 
OA [22, 24]. 115 
 116 
IL-1β signalling inhibitors 117 
IL-1β has been purported to be a driver of OA pathology [25] by mediating damage 118 
to articular cartilage tissue [6, 26, 27] and inhibiting the anabolic processes of 119 
articular chondrocytes [28]. Found in its active form in cartilage, synovial fluid and 120 
synovium, IL-1β inhibits type II collagen [8], aggrecan [8] and proteoglycan synthesis 121 
[29] and stimulates production of pro-inflammatory cytokines, MMPs and PGE2. 122 
Increased abundance of IL-1β has been reported in synovial fluid of both knee OA 123 
and ACL patients, compared to healthy individuals [30-33], and in the synovial 124 
membrane expression correlates with OA grade [9].   125 
 126 
Diacerein, a small molecule IL-1β inhibitor, reduces the number of IL-1 receptors 127 
resulting in a reduction in functional IL-1 heterodimer receptor complexes [34]. It has 128 
demonstrated “anti-arthritic” properties both in vitro [35] and in vivo in a murine 129 
model [36] through the inhibition of MMPs [37] and NO production [38]. In a 3yr 130 
RCT(NCT00451360), 507 hip OA patients received either Diacerein or placebo (2x50mg 131 
orally) daily. Although pain and functional impairment associated with OA remained 132 
unchanged, Diacerein significantly reduced JSN compared to placebo [39]. However, 133 
gastrointestinal adverse effects with Diacerein were a common, cause of treatment 134 
discontinuation, restricting its usage.It is not recommended for individuals aged over 135 
65 years.  136 
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 137 
Alternative IL-1 pathway inhibitors such as the human mAb AMG108 have been 138 
designed to directly target the IL-1 receptor.  In a RCT(NCT00110942)  of 160 patients 139 
with knee OA, AMG108 was well tolerated independent of dosage or route of 140 
administration. However, although marginal improvements in pain were noted in the 141 
AMG108 group, the difference was statistically insignificant and the clinical endpoint 142 
was not achieved [40]. 143 
 144 
Given the limited clinical efficacy with subcutaneous administration of IL-1β inhibitors 145 
and the potential for adverse systemic events, recent studies have focussed on intra-146 
articular (I.A) administration [41]. A RCT(NCT00110916)  involving 170 patients with 147 
painful knee OA administered either 50mg or 150mg of Anakinra (a IL-1β receptor 148 
antagonist), or placebo control.  Unfortunately, no improvement in WOMAC score or 149 
cartilage turnover was reported after 4 weeks [42]. However, patients were not pre-150 
selected on the basis of any confirmed synovitis. Thus it is possible that the study 151 
population contained a heterogeneous mix of responders and non-responders. 152 
 153 
Arachidonic acid pathway inhibitors 154 
Non-steroidal anti-inflammatory drugs (NSAIDs) are often prescribed to reduce OA 155 
pain [43]. Pharmacological they inhibit cyclooxygenase (COX) enzymes in the 156 
arachidonic acid pathway, leading to a reduction in prostaglandin synthesis, which 157 
are known mediators of pain and inflammation. Non-selective NSAIDs (nsNSAIDs) 158 
(e.g Ibuprofen, naproxen and Diclofenac), inhibit both COX-1 and COX-2 enzymes, 159 
and their efficacy in reducing pain, inflammation and swelling in patients with OA has 160 
been demonstrated in several clinical studies (NCT01461369, NCT01860833) [44-46]. 161 
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 162 
Critically, long-term administration of nsNSAIDs is associated with significant 163 
adverse events from GI perforation, ulceration and bleeding [47] due to the reduction 164 
of GI tract protective prostanoids; a process mediated by COX-1 [48]. Due to these 165 
issues, selective COX-2 inhibitors have been developed, including Celecoxib and 166 
Valdecoxib.  167 
 168 
In a RCT(NCT00650624), Valdecoxib (5mg, 10mg, and 20mg daily dosage) was 169 
compared to the nsNSAID naproxen (500mg twice daily dosage), in patients with 170 
moderate/severe knee OA. At 5mg and 10mg doses, the Valdecoxib group exhibited 171 
significantly reduced GI toxicity compared to the naproxen group [49]. Unfortunately, 172 
although clinical trials demonstrated a reduction in GI complications [50, 51], an 173 
increased risk of adverse cardiovascular events were noted [52]. This is attributed to 174 
the mode-of-action of selective COX-2 inhibitors which decrease prostacyclin 175 
production without altering thromboxane levels.  176 
 177 
An alternative approach is dual inhibition of leukotrienes and prostaglandins , by 178 
targeting both 5-lipoxygenase (LOX) activity and COX-2. One such COX/LOX 179 
inhibitor is Licofelone (Merckle GmbH). In preclinical models of OA, Licofelone has 180 
shown disease-modifying efficacy in reducing synovium hypertrophy, cartilage 181 
lesions and production of pro-inflammatory PGE2 and leukotrienes B4 [53, 54].  182 
 183 
Licofelone was shown to significantly reduce cartilage volume loss (vs nsNSAID 184 
alone) in a recent RCT of patients with knee OA [55]. Specifically, 355 knee OA 185 
patients received twice daily naproxen (500mg) or licofelone (200mg). Cartilage 186 
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volume and JSN was measured at baseline, 6, 12 and 24 months [55]. Global 187 
cartilage loss was significantly less in the licofelone group compared with naproxen 188 
[55]. Critically, no reported GI or CV toxicity at efficacious concentrations were 189 
recorded [56].  190 
 191 
Despite these promising results, Licofelone has not yet been submitted for regulatory 192 
approval. There is evidence to suggest that the rate of OA progression may increase 193 
in patients receiving long-term NSAID treatment. Radiological assessment of knee 194 
and hip OA progression found an increase in the risk of OA progression  in 195 
individuals on long-term Diclofenac treatment (>180 days) compared to individuals 196 
on short-term treatment (1-30 days) [57]. Indeed, in contrast to their efficacy in 197 
blocking pro-inflammatory responses, COX2 inhibitors have been reported to delay 198 
the resolution of inflammation in chronic inflammatory preclinical models [58]. 199 
Whether these data are the reason why Licofelone has not progressed since its 200 
positive PhIII data is unclear. 201 
 202 
NO inhibitors 203 
NO plays an important role in inflammatory processes and is considered a key 204 
mediator of cartilage destruction in OA [59]. NO and the inducible NO synthase 205 
(iNOS) are upregulated in preclinical animal models of OA [60] as well as in human 206 
OA chondrocytes [61], and mediate the release of pro-inflammatory cytokines. 207 
Indeed, NO can mediate many of the pathogenic effects of IL-1β through the 208 
activation of MMPs, the inhibition of proteoglycan and collagen synthesis and the 209 
enhancement of inflammation [62]. Preclinical studies have shown that iNOS KO 210 
mice are resistant to development of OA [63], and that pharmacological inhibition of 211 
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iNOS reduces OA progression and pain in the MIA rodent of OA [64] and in a canine 212 
model of OA [65] . 213 
 214 
Aa recent clinical trial investigated the safety and efficacy of a novel irreversible 215 
iNOS inhibitor (SD-6010) on slowing OA progression in a cohort of overweight and 216 
obese patients with knee OA(NCT00565812). Disappointingly, although the iNOS inhibitor 217 
was well tolerated, the drug failed to slow the rate of JSN versus placebo over a 218 
course of 96 weeks [66].  However, additional iNOS inhibitors are in development, 219 
including S-Methylisothiourea, which in preclinical models is effective in reducing NO 220 
and disease progression in the MIA rodent model of OA [67].  Whether this 221 
promising preclinical data translates into human efficacy is a critical question, but 222 
these are encouraging studies.   223 
 224 
Emerging anti-inflammatory drug targets 225 
Since efforts to develop effective disease modifying OA therapeutics against prime 226 
inflammatory drug targets have yet to bear fruit, ongoing research to better 227 
understand the inflammatory response in OA joint tissues is critical so that new drug 228 
targets can be identified. There are a number of different therapeutic approaches 229 
being investigated which may ultimately provide an effective anti-inflammatory 230 
therapeutic for OA patients, including non-pharmacological approaches such as 231 
nutraceuticals and gene therapy [68].  Below we summarise some of the promising 232 
emerging targets, based on their disease linkage to OA and available preclinical 233 
data.  234 
 235 
Synovitis associated cytokines 236 
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In addition to TNF-α and IL-1β, many additional cytokines and chemokines, 237 
detectable in both the synovial fluid and in serum, have also been associated with 238 
OA [69]. One notable example is IL-15 which has been associated with RA 239 
pathology. However, IL-15 may also play an important  role in early OA, since IL-15 240 
expression in synovial fluid [70], and in serum are associated with the progression of 241 
early knee OA [71] and  pain [72]. Similarly, IL-7 has been implicated in joint 242 
inflammation [73] since studies have shown it can mediate TNF-α production in the 243 
RA joint [74]. Importantly, recent studies have shown that IL-7 is expressed by 244 
articular chondrocytes and that IL-7 stimulation of cartilage induces MMP13 245 
production and proteoglycan loss [75].  246 
 247 
Critically, whether these inflammation-associated cytokines are central regulators of 248 
early OA disease pathology or purely biomarkers of an inflammatory tissue is an 249 
important question. This will require target validation studies in appropriate and 250 
translatable preclinical models, as well as in human ex-vivo tissues. One of the prime 251 
candidates for such studies is IL-17 since IL-17A polymorphisms correlate to OA 252 
susceptibility in particular patient cohorts [76]. In knee OA, IL-17 is elevated in both 253 
the serum and synovial fluid, and correlates with KL grade [77].  In vitro human 254 
chondrocyte studies have shown IL-17 stimulates the production of NO and MMPs 255 
[78], and decreases TIMP-2 and TIMP4 expression [79]. Given these data, studies 256 
that aim to modulate IL-17 expression or its signalling activity in appropriate models 257 
are an important next step.     258 
 259 
p38 pathway inhibitors 260 
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There is good evidence that the p38 MAPK signalling pathway is activated in OA, 261 
and is a prominent pathway which mediates pro-inflammatory cytokine signal 262 
transduction. In human OA articular cartilage, p38 is phosphorylated by several 263 
putative drivers of OA including IL-1β, TNFα and damage associated molecular 264 
patterns (DAMPs) such as fibronectin fragments [80, 81]. Furthermore, p38 inhibitors 265 
have shown efficacy in reducing cartilage degeneration in both the MIA OA model 266 
[82-84], and reducing pain in RA animal models [85].  267 
 268 
Clinically, a p38 inhibitor (PH-797804) is currently being tested for its analgesic 269 
efficacy when administered orally in patients with knee OA KL grade <2 (NCT01102660). 270 
However, due to the cell-type-dependent pro-inflammatory and anti-inflammatory 271 
functions of p38 MAPK [86], systemic delivery of p38 inhibitors may not be 272 
appropriate. An alternative approach is to develop therapeutics that target molecules 273 
downstream in the p38 MAPK pathway, thus providing a more selective targeting 274 
approach.   275 
 276 
MAPKAPK2 (MK2) is one of several kinases directly activated by p38 [87], and is 277 
known to post-transcriptionally regulate transcripts containing adenine rich elements 278 
[88] including TNF-α  and MMP-13. We have previously shown that MK2 is active in 279 
areas of cartilage damage, and that MK2 inhibition  is as effective as p38 inhibition in 280 
preventing the IL-1β-mediated secretion of PGE2 and MMPs [89]. The in vivo 281 
efficacy of MK2 inhibition in OA preclinical models has not yet been reported, but 282 
MK2 inhibitors have shown efficacy in an inflammatory bowel murine model [90]. 283 
 284 
 285 
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Toll-like receptors  286 
Several DAMPs are associated with OA including cartilage extracellular matrix 287 
fragments and plasma proteins that enter the synovial fluid. Binding of DAMPs to 288 
pattern recognition receptors such as Toll-like receptors (TLRs) can activate NFĸB-289 
mediated inflammatory signalling. Articular chondrocytes have been shown to 290 
express TLR1-9 [91], but studies on TLR4 have so far provided the strongest link to 291 
OA. In humans, TLR4 expression is associated with areas of cartilage damage [92], 292 
JSN [93], and the expression of pro-inflammatory cytokines including IL-1β, TNFα, 293 
PGE2 and NO [94]. Multiple agents that either bind to TLR4 agonists (e.g Pep-1), or 294 
modulate TLR4 signalling (e.g PPARdelta and BMP-7) can inhibit pro-inflammatory 295 
and pro-catabolic effects in chondrocytes [91, 95] and prevent cartilage loss in a 296 
murine model of OA [96]. Therefore, development of specific pharmacological TLR4 297 
inhibitors may be of therapeutic value.  298 
 299 
A number of studies have also examined the role of TLR2 in OA. Similarly to TLR4, 300 
its expression is associated with lesional areas of cartilage damage [92], and several 301 
reports have demonstrated that TLR2 stimulation induces the production of pro-302 
inflammatory cytokines [97-99] and cartilage degradation [92]. However, in vivo 303 
modulation of TLR2 in arthritic joint models has revealed conflicting results. Of 304 
concern, TLR2 knockout mice develop a more severe OA pathology [100], which 305 
could be due to compensatory developmental effects which have yet to be 306 
established. More promisingly, TLR2 mAbs have been shown to inhibit both the 307 
production of pro-inflammatory cytokines and reduce the development of arthritis in 308 
the collagen-induced arthritis (CIA) model [99]. The therapeutic utility of such TLR2 309 
mAbs in OA specific models has not yet been reported.  310 
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 311 
Adipose secreted cytokines 312 
The discovery that adipose tissue secretes cytokines (adipokines) has led to the 313 
current understanding of adipose tissue as an endocrine organ [101]. Adipokine 314 
release has been mechanistically linked to metabolic complications and the 315 
metabolic syndrome [102, 103] by contributing to the low-level pro-inflammatory 316 
state seen commonly in obese individuals [104].  317 
Critically, adipokine signalling is now receiving much attention in relation to OA joint 318 
pathophysiology largely due to the association between obesity and OA [104, 105] in 319 
both weight-bearing and non-weight bearing joints (e.g hands) [106].  Furthermore, 320 
differential expression of particular adipokines have been reported in OA serum and 321 
synovial fluid, which are capable to modulating cartilage catabolic and anabolic 322 
pathways [105]. 323 
 324 
One of the most widely studied adipokines is leptin, a product of the ob gene, which 325 
is known to regulate metabolism and appetite [107].  Leptin is increased in OA 326 
synovial fluid compared to non-OA controls [108].  Recombinant leptin, either alone 327 
or synergistically with IL-1β, induces MMP-1 and MMP-13 expression in primary 328 
human chondrocytes [109] and increases the production of inflammatory mediators 329 
including IL-1β, IL-6, IL-8 and PGE2 [110]. Due to the pro-inflammatory nature of 330 
leptin and its potential to drive cartilage catabolism, the recent development of 331 
peptide-based and antibody-based leptin antagonists could provide an effective 332 
therapeutic [111, 112]. 333 
 334 
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RNAi based therapeutics 335 
RNA interference (RNAi)-based therapeutics such as siRNAs represents a relatively 336 
new and largely untapped avenue of therapeutic potential [113]. Relatively cheap to 337 
design and produce, this class of therapeutic is highly attractive to drug discovery 338 
[114]. 339 
 340 
One of the greatest hurdles facing siRNA therapeutics is achieving successful in vivo 341 
delivery to the site of action. Unless protected, for example by complexing with 342 
cationic lipids, siRNAs rapidly degrade in serum [115]. Successful preclinical studies 343 
using naked siRNAs have predominantly been achieved where systemic delivery can 344 
be avoided, such as in airway disease models [116], or in ocular conditions where 345 
the siRNA can be delivered directly to the site of action [117]. 346 
 347 
Systemic in vivo delivery of anti-inflammatory siRNAs has produced positive results 348 
in preclinical models of inflammatory joint disease where cationic lipids have been 349 
utilised as delivery vehicles. For example, reduced arthritis disease severity has 350 
been reported in the CIA murine RA model using cationic lipids to deliver siRNA 351 
targeting TNFα [118] and siRNA targeting  a panel of pro-inflammatory mediators 352 
including TNFα, IL-1β, IL-6, IL-18 and cytosolic phospholipase A2α [119]. In addition, 353 
IA delivery of virally packaged siRNAs targeting TNFα have shown disease-354 
modifying efficacy in the murine CIA RA model and similarly siRNA targeting NFĸB in 355 
the rodent meniscus tear OA model [120]. 356 
 357 
Optimisation of the delivery of RNAi-based therapeutics into the joint is required, 358 
together with a greater understanding of their specificity before their utility as OA 359 
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therapeutics can be fully realised. However, given that a limited proportion of targets 360 
are considered tractable with either small molecule or mAb entities, this field 361 
represents a highly important one. Furthermore, since Next Generation Sequencing 362 
has now identified multiple families of non-coding RNAs (e.g microRNA and 363 
LincRNAs) [121], the number of potential targets for therapeutic intervention is set to 364 
markedly increase. Importantly, several of these non-coding RNAs have already 365 
been shown to regulate chondrocyte inflammatory responses. 366 
 367 
Stratification of OA patients for anti-inflammatory therapeutics  368 
 369 
Critically, for clinical trials of anti-inflammatory therapeutics, synovitis is not reported 370 
to be present in all patients with early OA.  However, one cohort where synovitis is 371 
believed to play a central role is post- traumatic OA, which is attributed to 12% of 372 
symptomatic OA of the hip, knee and ankle [122].  Electron microscopy analysis 373 
suggests that trauma induces a differential synoviocyte configuration compared to 374 
primary OA synovitis [123], and   increased cytokine expression has been 375 
documented after joint trauma in chondrocytes, synoviocytes, infiltrating immune 376 
cells, and synovial fluid [30, 124, 125]. 377 
 378 
Gender may also be an important factor to consider for trials of particular OA anti-379 
inflammatory therapeutics.  There are no large cohort studies that have reported 380 
differences in the degree of synovitis between male and female patients with OA 381 
using modern imaging techniques.  However, such imaging techniques cannot 382 
determine differences in individual inflammatory mediators.  For example, free levels 383 
of leptin have been reported to be higher in the joints of females with knee OA, 384 
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compared to males [126].  This finding could explain why the association between 385 
obesity and OA risk is reported to be greater in females [127], and suggests that 386 
therapeutics targeting leptin signalling could be more efficacious in female OA 387 
patients.  Furthermore, a longitudinal prospective follow-up study found that females 388 
exhibited a greater incidence of poly-articular OA, more rapid structural progression, 389 
and a more severe symptomatic disease [128]. The higher incidence of multi-joint in 390 
females with hip OA could indicate the presence of a systemic inflammatory OA 391 
driver which is not present to the same degree, in males [128].  In addition, the 392 
increase in incidence of OA in females rises dramatically post-menopause [129, 393 
130], with retrospective case-controlled studies demonstrating a protective and anti-394 
inflammatory role of estrogen in OA [131-133].  Indeed, in vitro studies have shown 395 
that estrogens enhance glucosaminoglycan synthesis [134], inhibit COX2 mRNA 396 
expression [135] and protect against TNF-α, oncostatin-M [136], and ROS induced 397 
damage [137].  Furthermore, modulation of estrogen signalling is itself a potential 398 
pipeline for developing a therapeuticHowever, estrogen receptor α or β agonists 399 
have failed to demonstrate anti-inflammatory efficacy in patients with RA [138]. 400 
 401 
This knowledge of the diverse OA patient population necessitates the requirement 402 
for clear patient stratification in clinical trials. The impact of not selecting the 403 
appropriate patient population was illustrated by clinical trials with the drug Iressa 404 
(AstraZeneca), an EGFR-targeted therapy for non-small cell lung cancer patients. 405 
Iressa originally failed to meet its clinical end point during a PhII trial. However, 406 
subsequent analysis showed those patients with EGFR mutation [139] had improved 407 
survival.  Not selecting the appropriate patient population masked the beneficial 408 
effect of the drug in the original clinical study.  Iressa was eventually approved 5 409 
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years after the original PhIII trial and several large costly follow-up clinical studies 410 
[139]. An important step towards identifying such clinical patient-selection 411 
biomarkers for clinical trials of OA anti-inflammatory therapeutics was recently made 412 
by Ruston and colleagues who  identified a subgroup of hip OA patients that are 413 
epigenetically and transcriptomically predisposed to a cartilage inflammatory 414 
phenotype due to demethylation of the promotors of inflammatory/immunity-related 415 
genes [140].  416 
 417 
Conclusions  418 
Increasing evidence that inflammation contributes to OA joint pathology, particularly 419 
in specific patient cohorts, places great importance on both the identification of new 420 
drug targets that mediate inflammation in the joint and the requirement to re-evaluate 421 
historical clinical trial data.  Preclinical studies have identified several promising 422 
targets for potential therapeutic development, and further opportunities will likely 423 
arise in the near future from new drug classes (such as RNAi therapeutics) and from 424 
the re-purposing of candidate drugs from other therapeutic research areas.  425 
 426 
Critical in the development of any future anti-inflammatory therapeutic will be the 427 
need to identify and select the appropriate patient cohort. Our review of the historical 428 
clinical trial data of anti-inflammatory therapeutics in OA patients reveals that trials 429 
have not selected or stratified patients on the basis of synovitis or other inflammatory 430 
biomarker measurements. As such, some of these reagents may be worth revisiting 431 
in the clinic in the context of an appropriately selected patient cohort. Ideally in such 432 
cases a specific genomic or proteomic patient-selection biomarker would be 433 
identified closely linked to the mechanism of action of the therapeutic being tested. In 434 
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the absence of such a specific biomarker, it would appear pertinent to select patients 435 
on the basis of overt synovitis from either MRI or imaging analysis of the joint. Such 436 
an approach will result in smaller and cheaper clinical trials, with a much greater 437 
chance to observe beneficial effects, and ultimately is the route to the development 438 
of a personalised OA therapeutic. 439 
 440 
Key Messages 441 
1) Inflammation is a contributor to OA joint pathology, particularly in specific patient 442 
cohorts. 443 
2) Preclinical studies have identified several promising targets for potential 444 
therapeutic development. 445 
3) Clinical trials have not detailed any patient selection based on synovitis or 446 
inflammatory biomarker measurement. 447 
 448 
Acknowledgment 449 
Figure 1 was produced using Omnigraffle 6.  Clinical trials were identified using 450 
www.clinicaltrials.gov. 451 
 452 
Disclosure statement 453 
The authors declare no conflict of interest 454 
 455 
Funding statement 456 
Funding for this work was provided by the University of Birmingham.  457 
 458 
  459 
20 
 
References 460 
1. Fernandez-Madrid F, Karvonen RL, Teitge RA, Miller PR, An T, Negendank WG: Synovial 461 
thickening detected by MR imaging in osteoarthritis of the knee confirmed by biopsy as 462 
synovitis. Magnetic resonance imaging 1995, 13(2):177-183. 463 
2. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, Walsh DA: 464 
Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003, 48(8):2173-2177. 465 
3. Hall M, Doherty S, Courtney P, Latief K, Zhang W, Doherty M: Synovial pathology detected 466 
on ultrasound correlates with the severity of radiographic knee osteoarthritis more than 467 
with symptoms. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2014, 468 
22(10):1627-1633. 469 
4. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory 470 
cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7(1):33-42. 471 
5. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B: Synovial tissue 472 
inflammation in early and late osteoarthritis. Annals of the rheumatic diseases 2005, 473 
64(9):1263-1267. 474 
6. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, Feige U, Poole AR: Role 475 
of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human 476 
osteoarthritic cartilage. Arthritis and rheumatism 2005, 52(1):128-135. 477 
7. Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL, Brockbank SM, Needham MR, Read 478 
SJ, Newham P: The identification of differentially expressed microRNA in osteoarthritic 479 
tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis and cartilage 480 
/ OARS, Osteoarthritis Research Society 2009, 17(4):464-472. 481 
8. Stove J, Huch K, Gunther KP, Scharf HP: Interleukin-1beta induces different gene expression 482 
of stromelysin, aggrecan and tumor-necrosis-factor-stimulated gene 6 in human 483 
osteoarthritic chondrocytes in vitro. Pathobiology 2000, 68(3):144-149. 484 
9. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M: Synovial membrane 485 
inflammation and cytokine production in patients with early osteoarthritis. The Journal of 486 
rheumatology 1997, 24(2):365-371. 487 
10. Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L: Increased level of cytokines 488 
and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007, 489 
38(3):151-156. 490 
11. Amin AR: Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting 491 
enzyme in human osteoarthritis. Osteoarthritis Cartilage 1999, 7(4):392-394. 492 
12. Aktas E, Sener E, Zengin O, Gocun PU, Deveci MA: Serum TNF-alpha levels: potential use to 493 
indicate osteoarthritis progression in a mechanically induced model. Eur J Orthop Surg Tr 494 
2012, 22(2):119-122. 495 
13. Stannus O, Jones G, Cicuttini F, Parameswaran V, Quinn S, Burgess J, Ding C: Circulating 496 
levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee 497 
cartilage loss in older adults. Osteoarthritis and Cartilage 2010, 18(11):1441-1447. 498 
14. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, 499 
Mumford R, Liew FY: Production of nitric oxide in the synovial membrane of rheumatoid 500 
and osteoarthritis patients. The Journal of experimental medicine 1996, 184(4):1519-1524. 501 
15. Dayer JM, Beutler B, Cerami A: Cachectin/tumor necrosis factor stimulates collagenase and 502 
prostaglandin E2 production by human synovial cells and dermal fibroblasts. The Journal of 503 
experimental medicine 1985, 162(6):2163-2168. 504 
16. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E: Effects of TNFalpha-antagonists on 505 
nitric oxide production in human cartilage. Osteoarthritis and cartilage / OARS, 506 
Osteoarthritis Research Society 2002, 10(4):327-332. 507 
17. Saklatvala J: Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of 508 
proteoglycan in cartilage. Nature 1986, 322(6079):547-549. 509 
21 
 
18. Rau R: Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal 510 
antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. 511 
Annals of the rheumatic diseases 2002, 61 Suppl 2:ii70-73. 512 
19. Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D: Tumour necrosis factor blockade 513 
for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double 514 
blind, randomised trial on structure modification. Annals of the rheumatic diseases 2012, 515 
71(6):891-898. 516 
20. Maksymowych WP, Russell AS, Chiu P, Yan A, Jones N, Clare T, Lambert RG: Targeting 517 
tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of 518 
the knee. Arthritis research & therapy 2012, 14(5):R206. 519 
21. Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, 520 
Mulleman D, Lukas C et al: Adalimumab in patients with hand osteoarthritis refractory to 521 
analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. 522 
Annals of the rheumatic diseases 2014. 523 
22. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M: Treatment of erosive osteoarthritis of the 524 
hands by intra-articular infliximab injections: a pilot study. Rheumatology international 525 
2009, 29(8):961-965. 526 
23. Guler-Yuksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van 527 
Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF et al: Treatment 528 
with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with 529 
rheumatoid arthritis. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 530 
2010, 18(10):1256-1262. 531 
24. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, Genovese MC: A 532 
pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of 533 
the hands. Journal of Rheumatology 2007, 34(6):1323-1327. 534 
25. Daheshia M, Yao JQ: The interleukin 1beta pathway in the pathogenesis of osteoarthritis. 535 
The Journal of rheumatology 2008, 35(12):2306-2312. 536 
26. Fan Z, Bau B, Yang H, Soeder S, Aigner T: Freshly isolated osteoarthritic chondrocytes are 537 
catabolically more active than normal chondrocytes, but less responsive to catabolic 538 
stimulation with interleukin-1beta. Arthritis and rheumatism 2005, 52(1):136-143. 539 
27. Pfander D, Heinz N, Rothe P, Carl HD, Swoboda B: Tenascin and aggrecan expression by 540 
articular chondrocytes is influenced by interleukin 1beta: a possible explanation for the 541 
changes in matrix synthesis during osteoarthritis. Annals of the rheumatic diseases 2004, 542 
63(3):240-244. 543 
28. Goldring MB, Fukuo K, Birkhead JR, Dudek E, Sandell LJ: Transcriptional suppression by 544 
interleukin-1 and interferon-gamma of type II collagen gene expression in human 545 
chondrocytes. J Cell Biochem 1994, 54(1):85-99. 546 
29. Nietfeld JJ, Wilbrink B, Den Otter W, Huber J, Huber-Bruning O: The effect of human 547 
interleukin 1 on proteoglycan metabolism in human and porcine cartilage explants. J 548 
Rheumatol 1990, 17(6):818-826. 549 
30. Marks PH, Donaldson ML: Inflammatory cytokine profiles associated with chondral damage 550 
in the anterior cruciate ligament-deficient knee. Arthroscopy 2005, 21(11):1342-1347. 551 
31. Bigoni M, Sacerdote P, Turati M, Franchi S, Gandolla M, Gaddi D, Moretti S, Munegato D, 552 
Augusti CA, Bresciani E et al: Acute and late changes in intraarticular cytokine levels 553 
following anterior cruciate ligament injury. Journal of orthopaedic research : official 554 
publication of the Orthopaedic Research Society 2013, 31(2):315-321. 555 
32. McNulty AL, Rothfusz NE, Leddy HA, Guilak F: Synovial fluid concentrations and relative 556 
potency of interleukin-1 alpha and beta in cartilage and meniscus degradation. Journal of 557 
orthopaedic research : official publication of the Orthopaedic Research Society 2013, 558 
31(7):1039-1045. 559 
22 
 
33. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K: Interleukin 1 beta and stromelysin 560 
(MMP3) activity of synovial fluid as possible markers of osteoarthritis in the 561 
temporomandibular joint. Journal of oral and maxillofacial surgery : official journal of the 562 
American Association of Oral and Maxillofacial Surgeons 1997, 55(1):20-27; discussion 27-563 
28. 564 
34. Martel-Pelletier J, Pelletier JP: Effects of diacerein at the molecular level in the 565 
osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010, 2(2):95-104. 566 
35. Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J: Diacerhein and rhein 567 
reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. 568 
Osteoarthritis Cartilage 2000, 8(3):186-196. 569 
36. Moore AR, Greenslade KJ, Alam CA, Willoughby DA: Effects of diacerhein on granuloma 570 
induced cartilage breakdown in the mouse. Osteoarthritis and cartilage / OARS, 571 
Osteoarthritis Research Society 1998, 6(1):19-23. 572 
37. Boittin M, Redini F, Loyau G, Pujol JP: [Effect of diacerhein (ART 50) on the matrix synthesis 573 
and collagenase secretion by cultured joint chondrocytes in rabbits]. Revue du rhumatisme 574 
1993, 60(6 Pt 2):68S-76S. 575 
38. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J: Diacerhein and rhein 576 
reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity 577 
while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J 578 
Rheumatol 1998, 25(12):2417-2424. 579 
39. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, Group EIS: Evaluation 580 
of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-581 
year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in 582 
OA of the Hip. Arthritis and rheumatism 2001, 44(11):2539-2547. 583 
40. Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, Sun YN, Banfield C, 584 
Vincent MS, Ni L et al: A randomized, double-blind study of AMG 108 (a fully human 585 
monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis 586 
research & therapy 2011, 13(4):R125. 587 
41. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P: Safety study of 588 
intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee 589 
osteoarthritis: a multicenter study. The Journal of rheumatology 2005, 32(7):1317-1323. 590 
42. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, 591 
Silver D, Appleton BE: Intraarticular injection of anakinra in osteoarthritis of the knee: a 592 
multicenter, randomized, double-blind, placebo-controlled study. Arthritis and rheumatism 593 
2009, 61(3):344-352. 594 
43. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. 595 
Gastroenterology 2001, 120(3):594-606. 596 
44. Gibofsky A, Hochberg MC, Jaros MJ, Young CL: Efficacy and safety of low-dose submicron 597 
diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Current 598 
medical research and opinion 2014, 30(9):1883-1893. 599 
45. Gallelli L, Galasso O, Falcone D, Southworth S, Greco M, Ventura V, Romualdi P, Corigliano A, 600 
Terracciano R, Savino R et al: The effects of nonsteroidal anti-inflammatory drugs on 601 
clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways 602 
in knee osteoarthritis. A randomized open label trial. Osteoarthritis and cartilage / OARS, 603 
Osteoarthritis Research Society 2013, 21(9):1400-1408. 604 
46. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI: Comparison of an antiinflammatory 605 
dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of 606 
patients with osteoarthritis of the knee. The New England journal of medicine 1991, 607 
325(2):87-91. 608 
47. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal 609 
antiinflammatory drugs. The New England journal of medicine 1999, 340(24):1888-1899. 610 
23 
 
48. Scheiman JM: NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterology clinics 611 
of North America 1996, 25(2):279-298. 612 
49. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP: Randomized placebo-controlled trial 613 
comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. 614 
The Journal of family practice 2002, 51(6):530-537. 615 
50. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, 616 
Hawkey CJ, Hochberg MC et al: Comparison of upper gastrointestinal toxicity of rofecoxib 617 
and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England 618 
journal of medicine 2000, 343(21):1520-1528, 1522 p following 1528. 619 
51. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark 620 
C, Agrawal NM, Eisen GM et al: Celecoxib versus naproxen and diclofenac in osteoarthritis 621 
patients: SUCCESS-I Study. The American journal of medicine 2006, 119(3):255-266. 622 
52. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: 623 
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute 624 
myocardial infarction in the elderly. Archives of internal medicine 2003, 163(4):481-486. 625 
53. Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, Tries S, 626 
Pelletier JP: In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces 627 
the progression of experimental osteoarthritis: suppression of collagenase 1 and 628 
interleukin-1beta synthesis. Arthritis Rheum 2001, 44(10):2320-2330. 629 
54. Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, Laufer S, Martel-Pelletier J: 630 
The inhibition of subchondral bone resorption in the early phase of experimental dog 631 
osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and 632 
cathepsin K. Bone 2004, 34(3):527-538. 633 
55. Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, Beaulieu AD, Abram 634 
F, Dorais M, Vignon E et al: Protective effects of licofelone, a 5-lipoxygenase and cyclo-635 
oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first 636 
multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009, 68(6):938-947. 637 
56. Kulkarni SK, Singh VP: Licofelone--a novel analgesic and anti-inflammatory agent. Current 638 
topics in medicinal chemistry 2007, 7(3):251-263. 639 
57. Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM: Is there an 640 
association between the use of different types of nonsteroidal antiinflammatory drugs and 641 
radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis and rheumatism 642 
2005, 52(10):3137-3142. 643 
58. Chia WT, Pan RY, Tseng FJ, Chen YW, Feng CK, Lee HS, Chang DM, Sytwu HK: Experimental 644 
osteoarthritis induced by surgical realignment of the patella in BALB/c mice. JBone Joint 645 
SurgBr 2010, 92(12):1710-1716. 646 
59. Bentz M, Zaouter C, Shi Q, Fahmi H, Moldovan F, Fernandes JC, Benderdour M: Inhibition of 647 
inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. 648 
Journal of cellular biochemistry 2012, 113(7):2256-2267. 649 
60. Hashimoto S, Takahashi K, Amiel D, Coutts RD, Lotz M: Chondrocyte apoptosis and nitric 650 
oxide production during experimentally induced osteoarthritis. Arthritis and rheumatism 651 
1998, 41(7):1266-1274. 652 
61. Scher J, Pillinger M, Abramson S: Nitric oxide synthases and osteoarthritis. Current 653 
rheumatology reports 2007, 9(1):9-15. 654 
62. Jarvinen K, Vuolteenaho K, Nieminen R, Moilanen T, Knowles RG, Moilanen E: Selective iNOS 655 
inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA 656 
cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA 657 
cartilage as detected by protein antibody array. Clinical and experimental rheumatology 658 
2008, 26(2):275-282. 659 
24 
 
63. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA: Progress in the development of 660 
selective nitric oxide synthase (NOS) inhibitors. Current pharmaceutical design 2002, 661 
8(3):177-200. 662 
64. More AS, Kumari RR, Gupta G, Lingaraju MC, Balaganur V, Pathak NN, Kumar D, Sharma AK, 663 
Tandan SK: Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-664 
induced osteoathritic pain: implication for osteoarthritis therapy. Pharmacology, 665 
biochemistry, and behavior 2013, 103(4):764-772. 666 
65. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, Martel-Pelletier J: 667 
Reduction in the structural changes of experimental osteoarthritis by a nitric oxide 668 
inhibitor. Osteoarthritis and Cartilage 1999, 7(4):416-418. 669 
66. Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, 670 
Abramson SB, Manning PT, Miller CG, Vignon E: A 2-year randomised, double-blind, 671 
placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-672 
6010), in patients with symptomatic osteoarthritis of the knee. Annals of the rheumatic 673 
diseases 2013, 72(2):187-195. 674 
67. More AS, Kumari RR, Gupta G, Lingaraju MC, Balaganur V, Pathak NN, Kumar D, Kumar D, 675 
Sharma AK, Tandan SK: Effect of iNOS inhibitor S-methylisothiourea in monosodium 676 
iodoacetate-induced osteoathritic pain: Implication for osteoarthritis therapy. 677 
Pharmacology Biochemistry and Behavior 2013, 103(4):764-772. 678 
68. Mobasheri A: The future of osteoarthritis therapeutics: targeted pharmacological therapy. 679 
Curr Rheumatol Rep 2013, 15(10):364. 680 
69. Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, Lindstrom TM, Hwang I, 681 
Boyer KA, Andriacchi TP et al: Plasma proteins present in osteoarthritic synovial fluid can 682 
stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther 2012, 14(1):R7. 683 
70. Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, Potter HG, Mandl L, Marx R, 684 
Rodeo S et al: Local cytokine profiles in knee osteoarthritis: elevated synovial fluid 685 
interleukin-15 differentiates early from end-stage disease. Osteoarthritis and cartilage / 686 
OARS, Osteoarthritis Research Society 2009, 17(8):1040-1048. 687 
71. Ling SM, Patel DD, Garnero P, Zhan M, Vaduganathan M, Muller D, Taub D, Bathon JM, 688 
Hochberg M, Abernethy DR et al: Serum protein signatures detect early radiographic 689 
osteoarthritis. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2009, 690 
17(1):43-48. 691 
72. Sun JM, Sun LZ, Liu J, Su BH, Shi L: Serum interleukin-15 levels are associated with severity 692 
of pain in patients with knee osteoarthritis. Disease markers 2013, 35(3):203-206. 693 
73. Hartgring SA, van Roon JA, Wenting-van Wijk M, Jacobs KM, Jahangier ZN, Willis CR, Bijlsma 694 
JW, Lafeber FP: Elevated expression of interleukin-7 receptor in inflamed joints mediates 695 
interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis and rheumatism 696 
2009, 60(9):2595-2605. 697 
74. van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP: Interleukin 7 stimulates tumour 698 
necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid 699 
arthritis. Annals of the rheumatic diseases 2003, 62(2):113-119. 700 
75. Long D, Blake S, Song XY, Lark M, Loeser RF: Human articular chondrocytes produce IL-7 and 701 
respond to IL-7 with increased production of matrix metalloproteinase-13. Arthritis 702 
research & therapy 2008, 10(1):R23. 703 
76. Han L, Lee HS, Yoon JH, Choi WS, Park YG, Nam SW, Lee JY, Park WS: Association of IL-17A 704 
and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a 705 
Korean population. Gene 2014, 533(1):119-122. 706 
77. Chen B, Deng Y, Tan Y, Qin J, Chen LB: Association between severity of knee osteoarthritis 707 
and serum and synovial fluid interleukin 17 concentrations. The Journal of international 708 
medical research 2014, 42(1):138-144. 709 
25 
 
78. Martel-Pelletier J, Mineau F, Jovanovic D, Di Battista JA, Pelletier JP: Mitogen-activated 710 
protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric 711 
oxide production in human osteoarthritic chondrocytes: possible role of transactivating 712 
factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). Arthritis 713 
Rheum 1999, 42(11):2399-2409. 714 
79. Tanigawa S, Aida Y, Kawato T, Honda K, Nakayama G, Motohashi M, Suzuki N, Ochiai K, 715 
Matsumura H, Maeno M: Interleukin-17F affects cartilage matrix turnover by increasing 716 
the expression of collagenases and stromelysin-1 and by decreasing the expression of their 717 
inhibitors and extracellular matrix components in chondrocytes. Cytokine 2011, 56(2):376-718 
386. 719 
80. Zhou Y, Millward-Sadler SJ, Lin H, Robinson H, Goldring M, Salter DM, Nuki G: Evidence for 720 
JNK-dependent up-regulation of proteoglycan synthesis and for activation of JNK1 721 
following cyclical mechanical stimulation in a human chondrocyte culture model. 722 
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2007, 15(8):884-893. 723 
81. Yasuda T, Julovi SM, Hiramitsu T, Yoshida M, Nakamura T: Requirement of mitogen-724 
activated protein kinase for collagenase production by the fibronectin fragment in human 725 
articular chondrocytes in culture. Modern rheumatology / the Japan Rheumatism 726 
Association 2004, 14(1):54-60. 727 
82. Brown KK, Heitmeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ: P38 MAP 728 
kinase inhibitors as potential therapeutics for the treatment of joint degeneration and 729 
pain associated with osteoarthritis. J Inflamm (Lond) 2008, 5:22. 730 
83. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J: In vivo 731 
selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental 732 
osteoarthritis is associated with a reduction in the development of structural changes. 733 
Arthritis Rheum 2003, 48(6):1582-1593. 734 
84. Boileau C, Martel-Pelletier J, Brunet J, Schrier D, Flory C, Boily M, Pelletier JP: PD-0200347, 735 
an alpha2delta ligand of the voltage gated calcium channel, inhibits in vivo activation of 736 
the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCalpha dependent effect. Ann 737 
Rheum Dis 2006, 65(5):573-580. 738 
85. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, 739 
Rieman DJ, Gowen M et al: Disease-modifying activity of SB 242235, a selective inhibitor of 740 
p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis and 741 
rheumatism 2000, 43(1):175-183. 742 
86. van den Blink B, Juffermans NP, ten Hove T, Schultz MJ, van Deventer SJ, van der Poll T, 743 
Peppelenbosch MP: p38 mitogen-activated protein kinase inhibition increases cytokine 744 
release by macrophages in vitro and during infection in vivo. J Immunol 2001, 166(1):582-745 
587. 746 
87. Gaestel M: MAPKAP kinases - MKs - two's company, three's a crowd. Nature reviews 747 
Molecular cell biology 2006, 7(2):120-130. 748 
88. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M: MAPKAP 749 
kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nature cell biology 1999, 750 
1(2):94-97. 751 
89. Jones SW, Brockbank SM, Clements KM, Le Good N, Campbell D, Read SJ, Needham MR, 752 
Newham P: Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates 753 
key biological pathways associated with OA disease pathology. Osteoarthritis and cartilage 754 
/ OARS, Osteoarthritis Research Society 2009, 17(1):124-131. 755 
90. Liu X, Wu T, Chi P: Inhibition of MK2 shows promise for preventing postoperative ileus in 756 
mice. The Journal of surgical research 2013, 185(1):102-112. 757 
91. Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, Weichhart T, Saemann M, 758 
Smolen JS: Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease 759 
in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and 760 
26 
 
antagonized by bone morphogenetic protein 7. Arthritis and rheumatism 2007, 56(6):1880-761 
1893. 762 
92. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, Kim HY: The catabolic pathway mediated 763 
by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis and rheumatism 764 
2006, 54(7):2152-2163. 765 
93. Sillat T, Barreto G, Clarijs P, Soininen A, Ainola M, Pajarinen J, Korhonen M, Konttinen YT, 766 
Sakalyte R, Hukkanen M et al: Toll-like receptors in human chondrocytes and osteoarthritic 767 
cartilage. Acta orthopaedica 2013, 84(6):585-592. 768 
94. Gomez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G: TLR4 signalling in 769 
osteoarthritis--finding targets for candidate DMOADs. Nature reviews Rheumatology 2015, 770 
11(3):159-170. 771 
95. Campo GM, Avenoso A, D'Ascola A, Scuruchi M, Prestipino V, Nastasi G, Calatroni A, Campo 772 
S: Adenosine A2A receptor activation and hyaluronan fragment inhibition reduce 773 
inflammation in mouse articular chondrocytes stimulated with interleukin-1beta. The FEBS 774 
journal 2012, 279(12):2120-2133. 775 
96. Wang Q, Pan X, Wong HH, Wagner CA, Lahey LJ, Robinson WH, Sokolove J: Oral and topical 776 
boswellic acid attenuates mouse osteoarthritis. Osteoarthritis and cartilage / OARS, 777 
Osteoarthritis Research Society 2014, 22(1):128-132. 778 
97. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, Feldmann M, Brennan 779 
F, Foxwell BM: The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to 780 
the inflammatory and destructive processes in a human model of rheumatoid arthritis. The 781 
American journal of pathology 2007, 170(2):518-525. 782 
98. Ehrentraut H, Meyer R, Schwederski M, Ehrentraut S, Velten M, Grohe C, Knuefermann P, 783 
Baumgarten G, Boehm O: Systemically administered ligands of Toll-like receptor 2, -4, and -784 
9 induce distinct inflammatory responses in the murine lung. Mediators of inflammation 785 
2011, 2011:746532. 786 
99. Komai-Koma M, Li D, Wang E, Vaughan D, Xu D: Anti-Toll-like receptor 2 and 4 antibodies 787 
suppress inflammatory response in mice. Immunology 2014, 143(3):354-362. 788 
100. Blom AB, van Lent, P.L., Abdollahi-Roodsaz, S., van de Kraan, P., van den Berg, W.: Elusive 789 
Role for Toll Like receptor 2 in Joint Patholgy in Experimental Osteoarthritis. Osteoarthritis 790 
and Cartilage 2011, 19(Supplement 1):S18. 791 
101. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. The Journal of clinical 792 
endocrinology and metabolism 2004, 89(6):2548-2556. 793 
102. Deng Y, Scherer PE: Adipokines as novel biomarkers and regulators of the metabolic 794 
syndrome. Annals of the New York Academy of Sciences 2010, 1212:E1-E19. 795 
103. Richette P, Poitou C, Garnero P, Vicaut E, Bouillot JL, Lacorte JM, Basdevant A, Clement K, 796 
Bardin T, Chevalier X: Benefits of massive weight loss on symptoms, systemic inflammation 797 
and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis 2011, 798 
70(1):139-144. 799 
104. Gomez R, Lago F, Gomez-Reino J, Dieguez C, Gualillo O: Adipokines in the skeleton: 800 
influence on cartilage function and joint degenerative diseases. Journal of molecular 801 
endocrinology 2009, 43(1):11-18. 802 
105. Thijssen E, van Caam A, van der Kraan PM: Obesity and osteoarthritis, more than just wear 803 
and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced 804 
osteoarthritis. Rheumatology (Oxford) 2015, 54(4):588-600. 805 
106. Cicuttini FM, Baker JR, Spector TD: The association of obesity with osteoarthritis of the 806 
hand and knee in women: a twin study. J Rheumatol 1996, 23(7):1221-1226. 807 
107. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 808 
1998, 395(6704):763-770. 809 
27 
 
108. Ku JH, Lee CK, Joo BS, An BM, Choi SH, Wang TH, Cho HL: Correlation of synovial fluid leptin 810 
concentrations with the severity of osteoarthritis. Clinical rheumatology 2009, 28(12):1431-811 
1435. 812 
109. Hui W, Litherland GJ, Elias MS, Kitson GI, Cawston TE, Rowan AD, Young DA: Leptin 813 
produced by joint white adipose tissue induces cartilage degradation via upregulation and 814 
activation of matrix metalloproteinases. Annals of the rheumatic diseases 2012, 71(3):455-815 
462. 816 
110. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Paivarinta U, Moilanen T, Moilanen E: 817 
Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic 818 
cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators 819 
of inflammation 2009, 2009:345838. 820 
111. Gertler A: Development of leptin antagonists and their potential use in experimental 821 
biology and medicine. Trends in endocrinology and metabolism: TEM 2006, 17(9):372-378. 822 
112. Babaei A, Zarkesh-Esfahani SH, Bahrami E, Ross RJ: Restricted leptin antagonism as a 823 
therapeutic approach to treatment of autoimmune diseases. Hormones (Athens) 2011, 824 
10(1):16-26. 825 
113. Scherer LJ, Rossi JJ: Approaches for the sequence-specific knockdown of mRNA. Nature 826 
biotechnology 2003, 21(12):1457-1465. 827 
114. Jones SW, Souza PM, Lindsay MA: siRNA for gene silencing: a route to drug target 828 
discovery. Current opinion in pharmacology 2004, 4(5):522-527. 829 
115. Turner JJ, Jones SW, Moschos SA, Lindsay MA, Gait MJ: MALDI-TOF mass spectral analysis of 830 
siRNA degradation in serum confirms an RNAse A-like activity. Molecular bioSystems 2007, 831 
3(1):43-50. 832 
116. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BS, 833 
Gait MJ, Lindsay MA: Lung delivery studies using siRNA conjugated to TAT(48-60) and 834 
penetratin reveal peptide induced reduction in gene expression and induction of innate 835 
immunity. Bioconjugate chemistry 2007, 18(5):1450-1459. 836 
117. Thakur A, Fitzpatrick S, Zaman A, Kugathasan K, Muirhead B, Hortelano G, Sheardown H: 837 
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers. 838 
Journal of biological engineering 2012, 6(1):7. 839 
118. Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T: Arthritic joint-targeting small 840 
interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid 841 
arthritis. J Pharmacol Exp Ther 2012, 340(1):109-113. 842 
119. Courties G, Baron M, Presumey J, Escriou V, van Lent P, Scherman D, Cantagrel A, van den 843 
Berg WB, Jorgensen C, Apparailly F et al: Cytosolic phospholipase A2alpha gene silencing in 844 
the myeloid lineage alters development of Th1 responses and reduces disease severity in 845 
collagen-induced arthritis. Arthritis and rheumatism 2011, 63(3):681-690. 846 
120. Chen LX, Lin L, Wang HJ, Wei XL, Fu X, Zhang JY, Yu CL: Suppression of early experimental 847 
osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific 848 
siRNA. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2008, 16(2):174-849 
184. 850 
121. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, 851 
Cassady JP et al: Chromatin signature reveals over a thousand highly conserved large non-852 
coding RNAs in mammals. Nature 2009, 458(7235):223-227. 853 
122. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA: Posttraumatic osteoarthritis: 854 
a first estimate of incidence, prevalence, and burden of disease. Journal of orthopaedic 855 
trauma 2006, 20(10):739-744. 856 
123. Soren A, Klein W, Huth F: The synovial changes in post-traumatic synovitis and 857 
osteoarthritis. Rheumatology and rehabilitation 1978, 17(1):38-45. 858 
28 
 
124. Cameron ML, Fu FH, Paessler HH, Schneider M, Evans CH: Synovial fluid cytokine 859 
concentrations as possible prognostic indicators in the ACL-deficient knee. Knee surgery, 860 
sports traumatology, arthroscopy : official journal of the ESSKA 1994, 2(1):38-44. 861 
125. Irie K, Uchiyama E, Iwaso H: Intraarticular inflammatory cytokines in acute anterior cruciate 862 
ligament injured knee. The Knee 2003, 10(1):93-96. 863 
126. Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, Pallu S, Mainard D, Netter P, Terlain 864 
B: Differential distribution of adipokines between serum and synovial fluid in patients with 865 
osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis 866 
Cartilage 2006, 14(7):690-695. 867 
127. Holliday KL, McWilliams DF, Maciewicz RA, Muir KR, Zhang W, Doherty M: Lifetime body 868 
mass index, other anthropometric measures of obesity and risk of knee or hip 869 
osteoarthritis in the GOAL case-control study. Osteoarthritis and cartilage / OARS, 870 
Osteoarthritis Research Society 2011, 19(1):37-43. 871 
128. Maillefert JF, Gueguen A, Monreal M, Nguyen M, Berdah L, Lequesne M, Mazieres B, Vignon 872 
E, Dougados M: Sex differences in hip osteoarthritis: results of a longitudinal study in 508 873 
patients. Annals of the rheumatic diseases 2003, 62(10):931-934. 874 
129. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G: A meta-analysis of sex 875 
differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 876 
2005, 13(9):769-781. 877 
130. Nadkar MY, Samant RS, Vaidya SS, Borges NE: Relationship between osteoarthritis of knee 878 
and menopause. J Assoc Physicians India 1999, 47(12):1161-1163. 879 
131. Cirillo DJ, Wallace RB, Wu L, Yood RA: Effect of hormone therapy on risk of hip and knee 880 
joint replacement in the Women's Health Initiative. Arthritis Rheum 2006, 54(10):3194-881 
3204. 882 
132. Spector TD, Nandra D, Hart DJ, Doyle DV: Is hormone replacement therapy protective for 883 
hand and knee osteoarthritis in women?: The Chingford Study. Ann Rheum Dis 1997, 884 
56(7):432-434. 885 
133. Bergink AP, van Meurs JB, Loughlin J, Arp PP, Fang Y, Hofman A, van Leeuwen JP, van Duijn 886 
CM, Uitterlinden AG, Pols HA: Estrogen receptor alpha gene haplotype is associated with 887 
radiographic osteoarthritis of the knee in elderly men and women. Arthritis Rheum 2003, 888 
48(7):1913-1922. 889 
134. Maneix L, Beauchef G, Servent A, Wegrowski Y, Maquart FX, Boujrad N, Flouriot G, Pujol JP, 890 
Boumediene K, Galera P et al: 17Beta-oestradiol up-regulates the expression of a functional 891 
UDP-glucose dehydrogenase in articular chondrocytes: comparison with effects of 892 
cytokines and growth factors. Rheumatology (Oxford) 2008, 47(3):281-288. 893 
135. Morisset S, Patry C, Lora M, de Brum-Fernandes AJ: Regulation of cyclooxygenase-2 894 
expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-895 
alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 1998, 25(6):1146-1153. 896 
136. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, 897 
Tanko LB, Karsdal MA: Effects of ovariectomy and estrogen therapy on type II collagen 898 
degradation and structural integrity of articular cartilage in rats: implications of the time 899 
of initiation. Arthritis Rheum 2006, 54(8):2441-2451. 900 
137. Claassen H, Schunke M, Kurz B: Estradiol protects cultured articular chondrocytes from 901 
oxygen-radical-induced damage. Cell Tissue Res 2005, 319(3):439-445. 902 
138. Cutolo M: Selective estrogen receptor agonism lacks clinical benefit in rheumatoid 903 
arthritis: comment on the article by van Vollenhoven et al. Arthritis Rheum 2010, 904 
62(12):3832-3833. 905 
139. Armour AA, Watkins CL: The challenge of targeting EGFR: experience with gefitinib in 906 
nonsmall cell lung cancer. European respiratory review : an official journal of the European 907 
Respiratory Society 2010, 19(117):186-196. 908 
29 
 
140. Rushton MD, Young DA, Loughlin J, Reynard LN: Differential DNA methylation and 909 
expression of inflammatory and zinc transporter genes defines subgroups of osteoarthritic 910 
hip patients. Annals of the rheumatic diseases 2015. 911 
141. Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, Lee EB: The efficacy of diacerein in 912 
hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clinical 913 
therapeutics 2013, 35(4):431-439. 914 
142. Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, 915 
Maxwell T: A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip 916 
osteoarthritis. Clinical rheumatology 2011, 30(11):1433-1446. 917 
143. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O: A new 918 
player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-919 
inflammatory cytokines in chondrocytes. Osteoarthritis and Cartilage 2008, 16(9):1101-920 
1109. 921 
144. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, van den Brand BT, van de Loo FA, van den 922 
Berg WB: Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 923 
activation. The American journal of pathology 2009, 175(5):2004-2013. 924 
145. Berry PA JS, Cicuttini FM, Wluka AE, Maciewicz RA.: Temporal relationship between serum 925 
adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a 926 
population with clinical knee osteoarthritis. Arthritis and rheumatism 2011, 63(3):700-707. 927 
146. Busso N, So A, Chobaz-Peclat V, Morard C, Martinez-Soria E, Talabot-Ayer D, Gabay C: Leptin 928 
signaling deficiency impairs humoral and cellular immune responses and attenuates 929 
experimental arthritis. J Immunol 2002, 168(2):875-882. 930 
931 
30 
 
Table 1: Completed RCTs of anti-inflammatory therapeutics in OA 932 
Target  
Class 
Mode-of-
action Drug 
Clinical Trial Data 
Phase Patient Cohort 
Clinical 
End Point Results 
TNFα 
inhibition TNFα mAb 
Adalimumab 
PhII 
(NCT00296894)
[19] 
Hand OA 
(60 patients) 
Incidence of 
new erosive 
interphalangeal 
joint 
n/s vs placebo 
PhI/II 
(NCT00686439)
[20] 
Knee OA (17 
patients) 
Pain 
(WOMAC). 
Reduction in 
joint pain 
PhII 
(NCT00597623)
[21] 
Refractory 
hand OA (99 
patients) 
Pain.  n/s vs placebo  
DLX105 PhI/IIa (NCT00819572)  
Painful knee 
OA (27 
patients) 
Pain (VAS) 
Completed 
2010, no 
results 
published. 
IL1β 
inhibition 
IL1β small 
molecule 
pathway 
inhibitor 
Diacerein 
PhII 
(NCT00451360)
[39]  
Hip OA (507 
patients) 
Pain, function 
and JSN. 
Significant 
reduction in 
JSN vs 
placebo. 
PhIV 
(NCT00685542)
[141] 
Hand OA (86 
patients) 
Pain 
(AUSCAN) n/s vs placebo 
IL-1R1 mAb AMG108 
PhII 
(NCT00110942)
[40] 
Knee OA 
(160 patients) 
Pain. No 
disease 
modification 
end-point. 
n/s vs placebo 
IL1 β 
recombinant 
protein inhibitor 
(i.a) 
Anakinra 
PhII 
(NCT00110916)
[42] 
 
Painful knee 
OA (170 
patients) 
Pain, stiffness 
and physical 
function 
(WOMAC). 
Cartilage 
turnover. 
n/s vs placebo 
Arachidon
ic acid 
pathway 
inhibitors 
COX-2 inhibitor 
Valdecoxib 
PhII 
(NCT00650624)
[49] 
Symptomatic 
OA of the 
knee (1019 
patients) 
Pain 
(WOMAC) 
 
Significant 
reduction in 
pain 
Lumiracoxib 
PhIII 
(NCT00154219)
[142] 
Primary Hip 
OA (1262 
patients) 
Pain (VAS) 
Significant 
reduction in 
VAS score and 
improvement in 
function 
5-lipoxygenase 
and cyclo-
oxygenase 
inhibitor 
Licofelone Unknown [55] Knee OA (355 patients) 
Cartilage 
volume and 
JSN by 
assessed by 
quantitative 
MRI 
Significant 
reduced 
cartilage 
volume loss. 
JSN remained 
unchanged 
NO 
inhibitors iNOS inhibitor SD-6010 
PhII/III 
(NCT00565812)
[66] 
Overweight 
patients with 
knee OA 
(1457 
patients) 
JSN n/s vs placebo 
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Abbreviations:  Ph, Phase; n/s, non-significant; WOMAC, Western Ontario and 933 
McMaster Universities Arthritis Index; OA, osteoarthritis; JSN, joint space narrowing; 934 
VAS, Visual Analogue Scale; NO, Nitric Oxide; IL1 β, Interleukin-1 Beta; TNFα, 935 
Tumour Necrosis Factor alpha; COX-2, cyclooxygenase-2; AUSCAN, 936 
Australian/Canadian Hand Osteoarthritis Index.  937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
  947 
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Table 2. Promising emerging targets for development of a DMOAD 948 
Target  
Class Target Disease Linkage 
Preclinical Validation 
In vitro In vivo 
Cytokines 
and 
chemokines 
IL7 Expressed by articular chondrocytes [75] 
Induces MMP13 and 
proteoglycan loss in 
cartilage [75] 
 
IL-15 
Elevated in synovial 
fluid of patients with 
early OA [143]. Serum 
levels associated with 
knee OA progression 
[71] and pain [72]. 
  
IL-17 
Polymorphisms 
correlate to OA 
susceptibility [76]. 
Elevated in both serum 
and synovial fluid in 
knee OA, and 
correlation to disease 
severity [77]. 
Stimulates production 
of NO and MMPs in 
human chondrocytes 
[78], and reduced 
TIMP expression [79]. 
 
p38 pathway 
inhibitors 
p38 
MAPK 
P38 activated by OA 
relevant pro-
inflammatory cytokines 
p38 inhibition blocks 
cytokine mediated 
production of PGE2, 
MMP3 and MMP13 in 
human chondrocytes 
[89] 
p38 inhibition reduced 
in cartilage loss in 
score in MIA OA 
model [82-84] 
MAPKAP
K2 (MK2) 
Active phospho MK2 in 
areas of OA cartilage 
damage. 
MK2 inhibition blocks 
cytokine mediated 
production of PGE2, 
MMP3 and MMP13 in 
human chondrocytes 
[89] 
 
Toll-like 
receptors 
TLR2 
Activated by DAMPS in 
OA synovial fluid. 
Expression high in 
areas of cartilage 
damage [92]. 
TLR2 induces cytokine 
production [97-99] and 
cartilage damage [92]. 
TLR2 mAbs reduce 
disease score in CIA 
model [99] 
TLR4 
Activated by DAMPS in 
OA synovial fluid. 
Expression high in 
areas of cartilage 
damage [92], and 
increased with JSN 
progression [93]. 
Activation promotes 
cytokine production in 
human chondrocytes 
[144]. Non-specific 
TLR4 inhibitors reduce 
pro-catabolic effects in 
chondrocytes [91, 95] 
TLR4 KO mice 
protected against IL-1β 
mediated OA [144]. 
Non-specific TLR4 
inhibitors protective for 
cartilage loss in murine 
OA model [96] 
Adipokines Leptin 
Elevated in OA serum 
or synovial fluid [108].   
Correlation between 
serum levels and 
cartilage loss at 2 years 
[145] 
Induces production of 
MMPs [109] and pro-
inflammatory cytokines 
[110] in chondrocytes. 
Leptin deficient mice 
(ob/ob) are protected 
from experimentally 
induced arthritis [146] 
RNAi 
therapeutics 
TNFa 
(siRNA) 
Elevated levels of TNFα 
in OA serum and 
synovial fluid [9-11]  
Inhibition of TNF-a 
production 
siRNA reduced 
disease score in CIA 
murine model [118] 
Pan-
cytokine 
(siRNA) 
Elevated levels of pro-
inflammatory cytokines 
in  OA synovial fluid [4, 
69] 
Inhibition of TNF-α, IL-
1β, IL-6, IL-18 and A2α 
production [118] 
siRNA reduced 
disease score in CIA 
murine model [118] 
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 949 
Abbreviations:  MMP, matrix metalloproteinase; OA, osteoarthritis; MAPK, mitogen 950 
activated protein kinase; DAMPS, damage associated molecular pattern molecules; 951 
siRNA, small interfering RNA; TLR, toll like receptor; KO, knockout; NO, nitric oxide; 952 
JSN, joint space narrowing. 953 
  954 
34 
 
 955 
Figure 1:  The relationship between joint inflammation and OA pathology.  956 
Cartilage degradation and fragmentation causes synovial inflammation, and 957 
increases production of pro-degradative (MMPs) and pro-inflammatory (IL-6, IL7, 958 
IL1β, IL-15, IL-17, TNFα) proteins. Synovium immune cell infiltration and obese 959 
adipose tissue contribute towards increased production of pro-inflammatory 960 
cytokines and thus increase the production of proteolytic enzymes which drive 961 
further cartilage breakdown.  Blue ovals represent current and potential drugs and 962 
their associated targets.   = Immune cells including B cells, T cells, and 963 
macrophages.  Abbreviations; IL, interleukin; MMP, matrix metalloproteinase; NO, 964 
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nitric oxide; OA, osteoarthritis; PGE2, prostaglandin E2; TNF, tumour necrosis factor; 965 
TLR: Toll–like receptor. 966 
 967 
